Director Harold Shlevin files intent to sell $1.84M in GALT shares
GALT has more than doubled off its 52-week low of $1.07 on light trading volume (0.3× avg).
Summary
Director Harold Shlevin filed a Form 144 indicating intent to sell 441,500 shares of Galectin Therapeutics, valued at approximately $1.84 million, following previous sales totaling $1.40 million in the last three months.
Key Events · Ownership and Investor Activity · GALT
-
Director Files Intent to Sell
Director Harold Shlevin has filed a Form 144, indicating his intent to sell 441,500 shares of common stock.
-
Significant Proposed Sale Value
The proposed sale is valued at approximately $1,836,640.00, representing a substantial transaction for an insider.
-
Pattern of Recent Sales
This proposed sale follows previous dispositions by Mr. Shlevin, who sold 228,706 shares for $1,395,405.21 in the past three months.
Analysis · GALT · Life Sciences
This Form 144 filing signals a significant intent to sell by Director Harold Shlevin, with the proposed transaction valued at $1.84 million. This amount is notable relative to the company's market capitalization. The filing also reveals that Mr. Shlevin has already sold an additional $1.40 million worth of shares in the preceding three months, suggesting a sustained pattern of reducing his stake. While the sale is likely pre-planned given the adoption date, the cumulative value of these dispositions could be perceived negatively by investors as it represents a substantial reduction in insider ownership.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GALT was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $244.1M. The 52-week trading range was $1.07 to $7.13. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.